Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) -- a new class of multifunctional biologics designed to address the most challenging intracellular drug ...

Researchers designed polymers that degrade MYC and KRAS by recruiting cellular machinery, slowing tumors and countering drug ...

Preventing the cell’s protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors. For decades, scientists have tried to stop cancer by disabling the ...

HYDRACs are a class of proteomimetic polymers designed to mark harmful proteins, like MYC and KRAS, for destruction rather than merely block their activity.

The growth protein, MYC, was consistently found with RBM42, which spurs MYC production, in human pancreatic tumors. Above, microscopy for MYC (red) and RBM42 (green) in a representative pancreatic ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...

M. Conacci-Sorrell et al., “Myc-nick: a cytoplasmic cleavage product of Myc that promotes α-tubulin acetylation and cell differentiation,” Cell, 142:480-93, 2010. Free F1000 Evaluation When Maralice ...

The findings were published in the journal Cell. The research was led by Leonie Uhl, Amel Aziba, and Sinah Löbbert, working with colleagues from the University of Würzburg (JMU), Massachusetts ...

Could this mark a shift in how we think about cancer therapy? At least in the laboratory, evidence suggests it may be. An international research team has succeeded in deciphering a key mechanism that ...